-+ 0.00%
-+ 0.00%
-+ 0.00%

Stifel Maintains Buy on Enliven Therapeutics, Raises Price Target to $82

Benzinga·08/06/2026 14:15:47
Listen to the news
Stifel analyst Dara Azar maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and raises the price target from $80 to $82.